How to Get Jatenzo in Washington: Prescriptions, Telehealth, and Pharmacy Access

How to Get Jatenzo in Washington
At a glance
- Drug / Jatenzo (oral testosterone undecanoate), manufactured by Tolmar
- DEA schedule / Schedule III controlled substance
- FDA-approved indication / male hypogonadism in adult men
- Dosing / 237 mg twice daily with food; adjusted to 158 mg or 316 mg based on serum testosterone
- Washington telehealth prescribing / permitted via synchronous audio-video visit
- Washington Medicaid / covered with prior authorization
- 503A compounding / available from licensed Washington pharmacies
- Prescriber types / MD, DO, NP (with prescriptive authority), PA
- Key lab requirement / two morning total testosterone levels below 300 ng/dL before starting
- Average cash price / approximately $650 to $900 per month without insurance
What Is Jatenzo and Why Does Access Matter in Washington?
Jatenzo is the brand name for oral testosterone undecanoate, the first FDA-approved oral testosterone replacement capsule for adult men with hypogonadism. The FDA granted approval in March 2019 based on a key trial by Swerdloff et al. (2020) showing that 87% of treated men achieved average serum testosterone concentrations within the normal range (300 to 1,100 ng/dL) at day 90.
Why Oral TRT Changed the Conversation
Before Jatenzo, testosterone replacement therapy (TRT) in the United States meant injections, topical gels, or transdermal patches. Each carries compliance or safety tradeoffs: injection-site pain, gel transfer risk to household contacts, or patch-site skin reactions. An oral option sidesteps all three. That matters in Washington, where geographic distance from specialty clinics in rural counties east of the Cascades makes a twice-daily capsule taken at home a practical advantage over weekly in-office injections.
Washington's Regulatory Environment
Washington state allows telehealth prescribing of Schedule III substances, which means a patient in Spokane, Yakima, or the San Juan Islands can consult a licensed provider by video and receive a Jatenzo prescription electronically. The Endocrine Society's 2018 clinical practice guideline recommends confirming hypogonadism with at least two morning testosterone levels below 300 ng/dL before initiating any form of TRT. Washington Medicaid follows this standard as a prerequisite for prior authorization.
Step-by-Step: Getting a Jatenzo Prescription in Washington
The path from symptoms to a filled prescription typically takes 2 to 4 weeks when labs, provider scheduling, and pharmacy processing align. Here is the sequence.
Step 1: Choose a Licensed Provider
Any Washington-licensed MD, DO, NP with prescriptive authority, or PA can prescribe Jatenzo. Endocrinologists and urologists handle most TRT cases, but primary care physicians and men's health telehealth clinics prescribe it regularly. The American Urological Association's 2018 guideline supports primary care initiation when the diagnosis is straightforward.
Step 2: Complete Baseline Labs
Your provider will order at minimum:
- Two fasting morning total testosterone levels drawn before 10 AM on separate days
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism
- Complete blood count (CBC) with hematocrit, since testosterone can raise red blood cell mass
- Comprehensive metabolic panel including liver enzymes (AST, ALT)
- Lipid panel, because the Jatenzo FDA label carries a warning about potential HDL reduction and LDL elevation
- PSA for men over 40, per Endocrine Society recommendations
Quest Diagnostics and Labcorp both operate draw sites across Washington. Many telehealth platforms generate lab orders that patients can walk into these sites without an additional appointment.
Step 3: Obtain Insurance Authorization or Choose Cash Pay
If your plan requires prior authorization (PA), your provider's office submits clinical documentation. For Washington Medicaid (Apple Health), PA requires confirmed testosterone below 300 ng/dL on two separate morning draws, documented signs or symptoms of hypogonadism, and absence of contraindications such as breast or prostate cancer. Turnaround is typically 5 to 10 business days. Commercial insurers in Washington vary: some cover Jatenzo on a specialty tier with PA, others exclude it.
Cash-pay patients can expect $650 to $900 per month at retail pharmacies. Tolmar offers a manufacturer copay card that can reduce out-of-pocket costs to as low as $75 per month for commercially insured patients, though this does not apply to government-funded plans.
Telehealth Prescribing of Jatenzo in Washington
Washington is one of the more telehealth-friendly states in the country. A synchronous audio-video visit satisfies the prescriber-patient relationship requirement for Schedule III controlled substances under Washington Administrative Code (WAC) 246-919-480.
How a Telehealth TRT Visit Works
The visit itself mirrors an in-person consultation. The provider reviews your lab results, medical history, current medications, and symptoms (fatigue, low libido, reduced muscle mass, depressed mood). Physical exam components that can be assessed visually (body habitus, gynecomastia) are documented during the video call. Testicular exam findings, if needed, may require a single in-person visit or a recent exam note from another provider.
Choosing a Telehealth Platform
Several national men's health telehealth companies are licensed in Washington. When evaluating a platform, verify three things: the prescriber holds an active Washington state license, the platform uses a DEA-registered prescriber for Schedule III medications, and they accept your insurance or offer transparent cash pricing. HealthRX connects Washington patients with board-certified providers who can evaluate, diagnose, and prescribe Jatenzo through a streamlined telehealth workflow.
Interstate Telehealth Considerations
If you split time between Washington and another state, the prescription must originate from a provider licensed in the state where you are physically located at the time of the visit. A Washington-licensed telehealth provider cannot legally prescribe to you while you are sitting in Oregon or Idaho, even if your home address is in Washington.
Pharmacy Options for Jatenzo in Washington
Once you have a valid prescription, filling it requires a pharmacy that stocks or can order brand-name Jatenzo or, alternatively, a 503A compounding pharmacy licensed to prepare oral testosterone undecanoate.
Retail and Specialty Pharmacies
Major chains (CVS, Walgreens, Costco Pharmacy, Rite Aid) and independent pharmacies across Washington can order Jatenzo from wholesale distributors. Because it is a Schedule III controlled substance, the pharmacy must maintain DEA registration and comply with Washington State Pharmacy Quality Assurance Commission rules. Specialty pharmacies affiliated with health systems like UW Medicine, Virginia Mason Franciscan Health, and MultiCare may carry it on formulary directly.
503A Compounding Pharmacies
Washington licenses 503A compounding pharmacies that can prepare testosterone undecanoate capsules from bulk pharmaceutical-grade ingredients pursuant to a patient-specific prescription. Compounded oral testosterone undecanoate typically costs 40% to 60% less than brand Jatenzo, though it is not FDA-approved and lacks the same bioequivalence data. The FDA's guidance on 503A compounding requires these pharmacies to compound in response to individual prescriptions, not in anticipation of demand.
Several Washington-based 503A pharmacies ship statewide. Confirm the pharmacy holds a current Washington State Pharmacy License and complies with USP 795 standards for non-sterile compounding.
Mail-Order and Shipping Logistics
Both brand Jatenzo and compounded oral testosterone undecanoate ship well because they are oral capsules, not temperature-sensitive biologics. Standard ground shipping within Washington (2 to 5 business days) is sufficient. No cold-chain packaging is required. Some specialty pharmacies offer same-day local delivery in the Seattle-Tacoma metro area.
Cost Breakdown and Insurance Navigation
The financial side of Jatenzo access in Washington depends heavily on insurance status.
Commercial Insurance
Many employer-sponsored plans in Washington place Jatenzo on Tier 3 or specialty tiers with copays ranging from $50 to $150 per month after PA approval. Plans through the Washington Health Benefit Exchange (state ACA marketplace) vary by carrier. Premera Blue Cross, Regence BlueCross BlueShield, Kaiser Permanente Washington, and Molina Healthcare each maintain distinct formularies.
Washington Medicaid (Apple Health)
Apple Health covers Jatenzo with PA for male hypogonadism. The PA form requires ICD-10 code E29.1 (testicular hypofunction), lab values, and a statement that the patient has no contraindications. Approval is typically valid for 12 months before renewal.
Medicare Part D
Medicare Part D plans may cover Jatenzo, but coverage varies by plan sponsor. The CMS Medicare Plan Finder tool can confirm whether a specific Part D plan includes oral testosterone undecanoate on formulary.
Cost-Saving Strategies
Tolmar's copay assistance program can reduce costs to $75 per month for eligible commercially insured patients. GoodRx and RxSaver coupons may lower the retail price at certain pharmacies. For patients choosing the compounded route, prices from Washington 503A pharmacies typically fall between $250 and $450 per month, depending on dose and capsule count.
Monitoring and Follow-Up After Starting Jatenzo
Starting Jatenzo is not a one-time event. Ongoing monitoring is required to ensure safety and dose optimization.
Early Follow-Up Labs
The Jatenzo prescribing information recommends checking serum testosterone 1 month after initiation or dose adjustment. The target trough (pre-dose) level is 300 to 1,100 ng/dL. In the Swerdloff et al. Trial, dose titration at day 42 based on serum levels achieved target range in 87% of men by day 90.
Hematocrit Surveillance
Testosterone therapy raises erythropoiesis. The Endocrine Society recommends checking hematocrit at baseline, at 3 to 6 months, then annually. A hematocrit above 54% warrants dose reduction or temporary discontinuation. In the Swerdloff trial, the incidence of polycythemia (hematocrit >54%) was 5.4%, comparable to injectable testosterone formulations [1].
Cardiovascular and Hepatic Monitoring
The FDA requires a boxed warning on Jatenzo regarding the potential for blood pressure increases. Mean systolic blood pressure rose by 3 to 5 mmHg in clinical trials. Liver function tests (AST, ALT) should be checked periodically because oral testosterone passes through hepatic first-pass metabolism, though the lymphatic absorption pathway of testosterone undecanoate reduces hepatic exposure compared to older oral androgens like methyltestosterone [2].
Ongoing Visit Cadence
Most Washington providers follow this schedule:
- Month 1: lab check (total testosterone trough, CBC)
- Month 3: repeat labs, blood pressure, symptom assessment
- Month 6: full panel including lipids, liver enzymes, PSA (if applicable)
- Annually: comprehensive lab panel, symptom review, hematocrit, cardiovascular risk assessment
Telehealth visits work well for these follow-ups because the key data points are lab values and symptom questionnaires, not physical examination findings.
Who Can Prescribe Jatenzo in Washington
Washington state scope-of-practice rules determine which providers can write a Schedule III prescription.
Physicians (MD and DO)
Any physician with an active Washington medical license and DEA registration can prescribe Jatenzo. No additional certification is required.
Nurse Practitioners
Washington grants NPs full practice authority. An ARNP with prescriptive authority and a DEA number can independently prescribe Schedule III substances without physician oversight. This expands access significantly in rural areas.
Physician Assistants
PAs in Washington prescribe under a practice agreement with a supervising physician. A PA with DEA registration can prescribe Jatenzo as long as the supervising physician's delegation agreement includes Schedule III controlled substances.
Naturopathic Physicians
Washington-licensed naturopathic physicians (NDs) have limited prescriptive authority. They may prescribe certain Schedule III through V substances listed in WAC 246-836-210, which includes testosterone. However, not all NDs carry DEA registration or routinely manage TRT, so patients should confirm before scheduling.
Transferring a Jatenzo Prescription to Washington
Patients relocating to Washington or visiting long-term can transfer an existing Jatenzo prescription under specific conditions.
In-State Transfer
Transferring between two Washington pharmacies follows standard Board of Pharmacy rules. The receiving pharmacy contacts the originating pharmacy, verifies the remaining refills, and processes the transfer electronically. Schedule III prescriptions may be transferred once between pharmacies unless both pharmacies share a real-time online database.
Out-of-State Transfer
Washington pharmacies can accept a controlled substance prescription transfer from an out-of-state pharmacy, provided the original prescription was valid in the issuing state. The receiving pharmacist must verify the prescriber's credentials and the prescription's authenticity. Some pharmacies require a new prescription from a Washington-licensed provider rather than a transfer, particularly for Schedule III drugs.
The simplest path for relocating patients: establish care with a Washington-licensed provider (in-person or telehealth), bring your records and recent labs, and have the new provider write a fresh prescription.
Timeline: From First Visit to First Dose
| Step | Typical Duration | |---|---| | Initial consultation (in-person or telehealth) | Day 1 | | Baseline lab draw and results | Days 2 to 5 | | Follow-up visit to review labs and prescribe | Days 5 to 7 | | Prior authorization (if required) | Days 7 to 17 | | Pharmacy fill and pickup or delivery | Days 17 to 21 | | Total (with PA) | 2 to 3 weeks | | Total (cash pay, no PA) | 1 to 2 weeks |
Patients paying cash and using a telehealth platform with integrated lab ordering can compress this timeline to under 10 days. PA-dependent patients should budget 3 weeks.
Frequently asked questions
›How do I get a Jatenzo prescription in Washington?
›What labs are needed before Jatenzo in Washington?
›Are there telehealth providers in Washington prescribing Jatenzo?
›How long until I receive Jatenzo in Washington?
›Can I transfer a Jatenzo prescription to Washington?
›Are 503A pharmacies in Washington licensed to ship oral testosterone undecanoate?
›Who can prescribe Jatenzo in Washington: MD vs NP vs PA?
›What documentation does prior authorization require in Washington?
›Does Washington Medicaid cover Jatenzo?
›Is compounded oral testosterone undecanoate cheaper than brand Jatenzo?
›Can I get Jatenzo without insurance in Washington?
›What are the main side effects of Jatenzo I should discuss with my Washington provider?
References
- Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. https://pubmed.ncbi.nlm.nih.gov/31773132/
- U.S. Food and Drug Administration. Jatenzo (testosterone undecanoate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_cda/index.cfm
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/29366564/
- U.S. Food and Drug Administration. Compounding and the FDA: current policy and guidance. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-current-policy-and-guidance
- Endocrine Society. Testosterone therapy in adult men with androgen deficiency syndromes. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/